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A unique problem frequently encountered with the therapeutically advantageous
oral sustained release dosage forms is their inability to reside in stomach and the proxi-
mal part of small intestine for a prolonged period of time. This led to the development
of various gastroretentive drug delivery systems (GRDDS). The various approaches ci-
ted in the literature (1–4) include floatation, mucoadhesion, sedimentation, swelling or
expansion, modified shape systems, or simultaneous administration of pharmacological
agents that delay gastric emptying.
Among the various attempts made, the floating drug delivery systems offer the most
effective and rational protection against early and random gastric emptying compared
to the other methods proposed for prolonging the gastric residence time of solid dosage
forms (4). However, the problems such as all or nothing emptying of single unit floating
dosage forms made them unreliable and irreproducible in prolonging the gastric resi-
dence time, which led to the development of multiple unit floating systems (5). The de-
velopment of mini-matrices is a promising area concerned with high control over the re-
lease rate of the drug combined with high flexibility of the adjustment of both the dose
and the release of a drug or drugs (6). The concept of multiple units is characterized by
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the fact that the dose is administered as a number of subunits, each one containing the
drug. The dose is then the sum of the quantity of the drug in each subunit and the func-
tionality of the entire dose is directly correlated with the functionality of individual sub-
units (7). Like other multiple unit systems, multiple tablets can be filled into hard gelatin
capsules that release these subunits after disintegration.
Fenoverine is an anti-spasmodic agent that restores smooth muscle motility and re-
lieves the distressing symptoms associated with irritable bowel syndrome and primary
dysmenorrhoea (8).
In the present study, biphasic GRDDS of fenoverine, as model drug, comprising an
immediate release loading dose tablet (LDT) and sustained release floating multiple ma-
trix tablets (FMMT) were developed and characterized for in vitro performance.
EXPERIMENTAL
Materials
Fenoverine and SpasmoprivTM 200 mg capsules were generous gifts from Euro-
drugs, India. HPMC K4M and HPMC 100 LV were obtained from ISP, India. Sodium bi-
carbonate, anhydrous citric acid and magnesium stearate were purchased from S.D.
Fine-Chem Ltd, India. Purified talc was purchased from E. Merck, India. All other chemi-
cals used were of analytical grade.
Methods
Preparation of the biphasic gastroretentive drug delivery system. – The total dose of feno-
verine for twice daily sustained release formulation was calculated based on pharma-
cokinetic data (9). The loading dose and the maintainance dose were 74 mg and 126 mg
of fenoverine, respectively. The total dose of GRDDS was 200 mg.
Preliminary formulations were studied to optimize the drug to polymer ratio and
effervescent composition (data not shown). Then, the FMMT was prepared with an opti-
mized concentration of effervescent composition. All formulation ingredients of FMMT
and LDT were sifted through a 420-mm aperture size sieve, homogeneously blended in a
mortar separately and directly compressed using 6-mm flat punches on a rotary compre-
ssion machine (Riddhi, India). The GRDDS marked 1, 2, 3, 4 comprising LDT and FMMT
marked 1, 2, 3, 4 equivalent to 200 mg of fenoverine, respectively, were placed in hard
gelatin capsules size 0 and evaluated. The qualitative and quantitative composition of
FMMT and LDT are shown in Table I.
Physical characterization of the blend and compressed FMMT and LDT. – Physical prop-
erties such as bulk density (rb), tapped density (rt), compressibility index and the angle
of repose of the final blend of FMMT were determined.
Compressed multiple tablets were characterized for mass and thickness variation
(n = 20). Crushing strength (n = 6) was measured with a Monsanto tester Campbell
Electronics (India), friability (n = 6), with a Roche type friabilator. The drug content in
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each formulation was determined by triturating 20 tablets in a mortar and powder equi-
valent to the average mass was added in 100 mL of 0.1 mol L–1 hydrochloric acid, fol-
lowed by shaking for 30 minutes. The sample was analyzed by the HPLC method (10).
Tablet density. – The density of the tablets (in g cm–3) was calculated from tablet height,
diameter and mass using the equation:
D = W/ [(m/2)2 ´ p ´ h]
where W is the mass of a tablet, m is the tablet diameter, p is the circular constant, and h
is the tablet height.
Floating behavior. – Buoyancy lag time and duration of buoyancy were determined in
the USP dissolution apparatus II (11) with 0.1 mol L–1 HCl and simulated gastric fluid
(enzyme free SGF). The time between the tablet introduction into the medium and its
buoyancy in the medium was taken as the buoyancy lag time and the duration of the
tablet remaining buoyant was observed visually.
In vitro drug release studies. – The release of fenoverine from FMMT and biphasic
GRDDS was studied using a USP (11) dissolution apparatus II (Labindia, India). The
dissolution media were 900 mL 0.1 mol L–1 HCl and SGF (enzyme free) maintained at
37 ± 0.5 °C and rotation speed of 50 rpm. Aliquots of 5 mL were collected at predeter-
mined time intervals, filtered through a 0.45-mm membrane filter and replenished with
an equivalent volume of fresh medium. Drug contents in the samples were determined
by HPLC after suitable dilutions.
Drug release modeling. – The suitability of several equations, reported in the litera-
ture to identify the mechanism(s) of fenoverine release (12, 13), was tested with respect
to the release data.
The release profiles were compared by a statistically derived mathematical index,
similarity factor (f2) (14) using theoretical profile as reference. The two dissolution pro-
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Table I. Composition of the biphasic fenoverine gastroretentive drug delivery system
Ingredient (mg per tablet) FMMT1 FMMT2 FMMT3 FMMT4 LDT
Fenoverine 42.00 42.00 42.00 42.00 74.00
HPMC K 4M 63.00 47.25 31.50 15.75 –
HPMC K 100 LV – 15.75 31.50 47.25 –
Sodium bicarbonate 20.00 20.00 20.00 20.00 –
Citric acid 5.00 5.00 5.00 5.00 –
Talc 2.00 2.00 2.00 2.00 2.00
Magnesium stearate 2.00 2.00 2.00 2.00 2.00
Cross caramellose sodium – – – – 13.00
Lactose – – – – 44.00
Total tablet mass (mg) 134.00 134.00 134.00 134.00 135.00
files are considered to be similar if f2 value is higer than 50 (between 50 and 100). The
dissolution efficiency (DE) (15) at 2, 6 and 8 h, t50% and t75% were also determined from
the dissolution profiles for each formulation.
Stability studies. – Optimized formulation was kept in the humidity chamber (LabTop,
India) maintained at 40 °C and 75 % relative humidity for 3 months. At the end of stud-
ies, the formulation was subjected to a drug assay, floating behavior testing and in vitro
dissolution studies. For the comparison of release profiles of initial and aged samples,
the similarity factor f2 was calculated.
RESULTS AND DISCUSSION
Physical properties of the final blend and compressed FMMT and LDT
The floating multiple matrix tablets of fenoverine were prepared by the effervescent
technique using methocel (K4M, K100LV). The combination of two different grades of
HPMC was utilized to obtain the desired buoyant characteristics and to maintain the
FMMT integrity for 12 h. The blend of the final batches showed bulk density of 0.55 ± 0.08
g cm–3 and tapped density of 0.64 ± 0.10 g cm–3 indicating desirable flow properties.
Further, the angle of repose showed a value of < 30°, compressibility below 15 %, indi-
cating good flow properties of the formulations.
Physical characteristics of the loading dose tablet and floating multiple matrix tab-
lets are shown in Table II. The drug content of FMMT and LDT was 101.1 ± 1.1 and 100.4
± 1.6 %, respectively (n = 3).
Buoyancy and density
The density of FMMT formulations was 1.202, 1.195, 1.225 and 1.234 g cm–3, respec-
tively. Though the density of formulated tablets was higher than 1.0 g cm–3, they rema-
ined buoyant for 12 h with a lag time of 4.16 to 5.22 minutes. The optimized concentra-
tion of the effervescent mixture (sodium bicarbonate and citric acid) contributed to the
buoyancy of all tablets.
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FMMT1 134.3 ± 1.0 4.1 ± 0.3 0.8 ± 0.1 42.3 ± 1.1 4.16 ± 0.3
FMMT2 133.5 ± 1.6 4.3 ± 0.4 0.6 ± 0.1 41.9 ± 1.5 5.22 ± 0.7
FMMT3 135.4 ± 1.7 5.1 ± 0.1 0.5 ± 0.1 42.6 ± 0.3 4.93 ± 0.3
FMMT4 136.0 ± 2.2 4.5 ± 0.2 0.6 ± 0.1 43.1 ± 0.9 4.74 ± 0.6
LDT 134.2 ± 2.8 5.3 ± 0.3 0.5 ± 0.1 74.3 ± 1.6 –
Mean ± SD: a n = 20, b n = 6, c n = 3.
In vitro release studies
Ideally, a sustained release formulation should release the required quantity of drug
with predetermined kinetics in order to maintain an effective drug plasma concentra-
tion. To achieve this, the delivery system should be formulated so that it releases the
drug in a predetermined and reproducible manner. The release of fenoverine from bi-
phasic GRDDS was analyzed by plotting the cumulative percent drug released against
time. Figs. 1a and b show the in vitro drug release profile of fenoverine in 0.1 mol L–1
HCl and SGF (enzyme free) from biphasic GRDDS. The biphasic GRDDS remains buoy-
ant in dissolution media with liberation of FMMT and LDT after 10–15 minutes. There
was an initial burst release of fenoverine from the gastroretentive system, which can be
attributed to the LDT, and release of fenoverine from FMMT was sustained over 12 h
compared to conventional commercial capsules which released the complete drug within
30 minutes. The initial burst release of 47.2 ± 1.8 % in 0.1 mol L–1 HCl and 41.5 ± 1.6 % in
SGF (enzyme free) from GRDDS was found during the first hour. The amount of drug
released after 12 h (Q12) from biphasic GRDDS was found to be 102.4 ± 1.6 % in 0.1 mol
L–1 HCl and 98.5 ± 2.2 % in SGF (enzyme free). The drug release from FMMT was sus-
tained for a prolonged period of time due to the viscous nature of the HPMC matrix
through which drug diffuses. Replacement of HPMC 100LV grade with HPMC K4M hel-
ped increase the drug release within 12 h and maintained the integrity and buoyancy of
the FMMT formed. The increased drug release from FMMT with high concentration of
HPMC K100LV compared to the FMMT containing its smaller amount may be due to
matrix erosion in the former and swelling diffusion and a slight erosin mechanism in the
latter. However, the matrix containing a high viscosity grade of polymer with large mo-
lecular mass mainly results in swelling properties with little erosion and vice versa. In-
tegrity and floating properties of FMMT were thus maintained.
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Fig. 1. Dissolution profiles of fenoverine from biphasic GRDDS in: a) 0.1 mol L–1 HCl, b) SGF (en-
zyme free) (mean ± SD, n = 6).
Drug release pattern from GRDDS
The results of kinetic models for fenoverine release from biphasic GRDDS are
shown in Table III. The coefficient of determination (R2) was used as an indicator of the
best fitting for each of the models considered. The results reveal that all formulations of
biphasic GRDDS best fit in the zero-order model, in both 0.1 mol L–1 HCl and SGF (en-
zyme free). The mechanism of drug release from these tablets was found to be diffusion,
as seen from high R2 values of the Higuchi model.
The optimized GRDDS formulation was selected based on the similarity factor (f2)
values of all GRDDS and other dissolution parameters such as dissolution efficiency (DE)
at 2, 6 and 8 h, t50% and t75% and characteristics of GRDDS3 (Table IV). The similarity
factor (f2) of GRDDS3, when compared to the theoretical release profile in 0.1 mol L–1
HCl, was observed to be 91.5, which was higher than for the other formulations, and
61.4 in SGF, which was well above 50 indicating that the drug release pattern was simi-
lar to the theoretical release profile. The other independent model parameters, such as
dissolution efficiency, also revealed that the drug release profile from GRDDS3 was simi-
lar to the theoretical profile.
Influence of media on drug release
The fenoverine release in 12 h from optimized biphasic GRDDS3 in 0.1 mol L–1 HCl
and SGF (enzyme free) was found to be 97.7 and 94.4 %, respectively. t-Test indicated no
statistically significant difference in drug release between the two media. However, the
similarity factor (f2) of the drug release from GRDDS3 in 0.1 mol L–1 HCL and SGF was
found to be 59.4, thus indicating that the drug release in both media was similar.
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0.1 mol L–1 HCl
GRDDS1 89.7 ± 0.1 0.975 0.990 0.980
GRDDS2 89.1 ± 0.1 0.965 0.990 0.994
GRDDS3 97.7 ± 0.1 0.991 0.999 0.974
GRDDS4 102.4 ± 0.1 0.970 0.991 0.983
SGF (enzyme free)
GRDDS1 81.7 ± 1.1 0.992 0.996 0.964
GRDDS2 81.6 ± 0.4 0.986 0.998 0.980
GRDDS3 94.4 ± 0.2 0.991 0.999 0.970
GRDDS4 98.5 ± 0.3 0.983 0.996 0.969
a Drug released in 12 h. Values represent mean ± SD, n = 3.
Stability studies
In view of the potential utility of the formulation, stability studies were carried out
at 40 °C and 75 % RH for three months (for accelerated testing) to assess their long-term
stability. Analysis of the dissolution data (Fig. 2), after storage for three months, showed
no significant change in the release pattern indicating that the two dissolution profiles
were similar (f2 > 50). The other parameters evaluated were comparable with initial val-
ues.
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2 h 6 h 8 h
0.1 mol L–1 HCl
Theoretical release 2.0 7.0 50 70 80 –
GRDDS1 2.0 8.0 55.9 78.2 83.6 80
GRDDS2 2.1 7.6 55.0 76.6 85.8 85
GRDDS3 1.7 7.0 52.4 72.0 81.1 92
GRDDS4 1.6 5.8 50.2 74.1 84.5 70
SGF (enzyme free)
GRDDS1 3.6 10.4 52.1 69.2 80.4 50
GRDDS2 3.3 10.5 54.6 73.1 81.0 53
GRDDS3 3.0 8.3 47.2 67.5 77.5 61
GRDDS4 3.0 8.0 45.1 67.8 76.2 68




















Fig. 2. Dissolution profile of
GRDDS3 after storage at 40 °C
and 75 % RH (mean ± SD, n =
6).
CONCLUSIONS
On the basis of buoyancy and in vitro release kinetics, it was concluded that the op-
timized formulation containing 200 mg of fenoverine is a suitable GRDDS. FMMT was
observed to be rigid, buoyant and initially showed no fragmentation because of its physi-
cal characteristics; it became soft at the end of the drug release studies. Biphasic GRDDS
is characterized by the initial burst release (LDT) followed by a slow zero-order release
pattern (FMMT) that shows high flexibility in modulating the delivery of the initial loa-
ding dose and the sustained dose. A further in vivo study has to be carried out to assess
the bioavailability of the drug form biphasic GRDDS.
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S A @ E T A K
Priprava i evaluacija dvofazi~nih plutaju}ih tableta fenoverina
SURESH BANDARI, CHANDRA MOHAN EAGA, ASHOK THADISHETTY i MADHUSUDAN RAO YAMSANI
U radu je opisan razvoj bifazi~nog sustava za isporuku fenoverina s produljenim
zadr`avanjem u `elucu radi odr`avanja konstantne koncentracije lijeka u plazmi. Sustav
je dobiven metodom izravne kompresije, a sastoji se od tablete za inicijalno doziranje i
matriksne tablete za plutanje. Osloba|anje lijeka iz bifazi~nog GRDDS u 0,1 mol L-1 HCl
i SGF (bez enzima) bilo je produljeno vi{e od 12 h, a sustav je pokazao plutaju}a svoj-
stva. Ispitivanja stabilnosti pokazala su da nema zna~ajne promjene u profilu osloba|a-
nja (f2 > 50). Na temelju kinetike osloba|anja mo`e se zaklju~iti da su plutaju}e vi{esloj-
ne matriksne tablete s HPMC posebno pogodan sustav za isporuku fenoverina u `elucu
s kinetikom osloba|anja nultog reda.
Klju~ne rije~i: bifazi~no osloba|anje, zadr`avanje u `elucu, vi{eslojne matriksne tablete, kinetika
osloba|anja
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